Clinical Trials Using FASN Inhibitor TVB-2640

Clinical trials are research studies that involve people. The clinical trials on this list are studying FASN Inhibitor TVB-2640. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-2 of 2
  • FASN Inhibitor TVB-2640, Paclitaxel, and Trastuzumab in Treating Patients with HER2 Positive Advanced Breast Cancer

    This phase II trial studies how well FASN inhibitor TVB-2640, paclitaxel, and trastuzumab work in treating patients with HER2 positive breast cancer that has spread to other places in the body. FASN inhibitor TVB-2640 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as trastuzumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving FASN inhibitor TVB-2640, paclitaxel, and trastuzumab may work better in treating patients with HER2 positive breast cancer.
    Location: 3 locations

  • FASN Inhibitor TVB-2640 in Treating Patients with Colon or Other Cancers That Can Be Removed by Surgery

    This randomized phase I trial studies how FASN inhibitor TVB-2640 works in treating patients with colon or other cancers that can be removed by surgery. FASN inhibitor TVB-2640 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: University of Kentucky / Markey Cancer Center, Lexington, Kentucky